Correction to: Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis (CNS Drugs, (2022), 36, 6, (569-589), 10.1007/s40263-022-00920-6)

Per Soelberg Sorensen*

*Corresponding author af dette arbejde

Abstract

This article was made available online at https://link.springer.com/article/10.1007/s40263-022-00920-6 on 19 May 2022. An error was subsequently identified in the article, and the following correction should be noted: Page 14, column 1, section 7.3, paragraph 1, lines 1-4: The following sentences, which previously read: “Ofatumumab is a fully human anti-CD20 monoclonal antibody and the B-cell-depleting drug most recently approved for the treatment of RRMS. It is administered subcutaneously at a dose of 30 mg every 4 weeks.” Should read: “Ofatumumab is a fully human anti-CD20 monoclonal antibody and the B-cell-depleting drug most recently approved for the treatment of RRMS. It is administered subcutaneously at a dose of 20 mg every 4 weeks.” The original article has been corrected.

OriginalsprogEngelsk
Publikationsdatoaug. 2022
Udgave8
Vol/bind36
Antal sider1
DOI
StatusUdgivet - aug. 2022
NavnCNS Drugs
ISSN1172-7047

Fingeraftryk

Dyk ned i forskningsemnerne om 'Correction to: Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis (CNS Drugs, (2022), 36, 6, (569-589), 10.1007/s40263-022-00920-6)'. Sammen danner de et unikt fingeraftryk.

Citationsformater